C4 Therapeutics
NEWS
The FDA had a busy week, approving drugs, greenlighting clinical trials and other regulatory activities for Immuneering, Amylyx, Sarepta, Sanofi, and Regeneron and more.
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
Shares fell in several life sciences companies at the close of the market Friday on apparently lackluster early data from their respective research projects. We look into each one below:
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
This followed a report that found that some trustees had, perhaps, taken advantage of this close connection with startups and research programs for their financial gain.
The company says it plans to file an IND for the candidate, dubbed CFT8919, by the middle of next year.
Company stock began trading on the Nasdaq this morning under the ticker symbol CCCC. The upsized IPO is expected to close Oct. 6.
Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
JOBS
IN THE PRESS